Combination therapies for the treatment of cancer
Inventors
Von Roemeling, Reinhard • Ugolkov, Andrey • Martell, Robert
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure relates to methods of treating certain diseases and disorders (e.g., cancer) with a combination of an IRAK4 inhibitor, a BCL-2 inhibitor, and a nucleoside analog.
Core Innovation
The invention relates to a method of treating cancer in a subject by conjointly administering a pyrimidinyl nucleoside analog, a BCL-2 inhibitor, and an IRAK4 inhibitor. The IRAK4 inhibitor is defined as having a structure represented by formula (II) or a pharmaceutically acceptable salt thereof, with specified structural-variable constraints for X1, X2, X3, A, Y, Z, R1, R2, R3, Ra, Rb, and indices m, n, and p.
The structural-variable constraints specify that X1 and X3 independently are CH or N, while X2 is CR2 or N, with the condition that one and not more than one of X1, X2, or X3 is N. A is O or S, Y is —CH2— or O, and Z is aryl or heterocyclyl. The substituents and ranges for R1, R2, and R3 are constrained using halo, optionally substituted heterocyclyl, optionally substituted aryl, cycloalkyl, hydroxyl, and —NRaRb options, together with indices m=0/1/2, n=0/1/2, and p=0/1.
The described cancer treatment context is supported by the combination of an IRAK4 inhibitor with agents including venetoclax as a BCL-2 inhibitor and azacitidine as a nucleoside analog. The document further identifies a clinical candidate targeting IRAK4 (Compound 1) and relates IRAK4 to an IL-1 receptor-associated kinase 4 (IRAK4) survival signaling pathway involving IL-1R/TLR–MYD88–IRAK4–NF-κB.
Claims Coverage
The independent claim covers a conjoint cancer-treatment method that combines three classes of agents: a pyrimidinyl nucleoside analog, a BCL-2 inhibitor, and an IRAK4 inhibitor defined by formula (II) with detailed structural constraints. No other independent claims are present in the provided claim set.
Conjoint administration of pyrimidinyl nucleoside analog, BCL-2 inhibitor, and IRAK4 inhibitor defined by formula (II)
A method of treating cancer in a subject comprising conjointly administering to a subject in need thereof a pyrimidinyl nucleoside analog, a BCL-2 inhibitor and an IRAK4 inhibitor with a structure represented by formula (II) or a pharmaceutically acceptable salt thereof, wherein the IRAK4 inhibitor structure is defined by the specified X1, X2, X3, A, Y, Z, R1, R2, R3, Ra, Rb, and indices m, n, and p constraints.
Across the provided independent claim, coverage is centered on conjoint administration combining a pyrimidinyl nucleoside analog, a BCL-2 inhibitor, and an IRAK4 inhibitor whose structure is restricted to the formula (II) scaffold with explicit heteroatom and substituent/index constraints.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treatment of cancer in a subject using conjoint administration of a pyrimidinyl nucleoside analog, a BCL-2 inhibitor, and an IRAK4 inhibitor.
Targeting hematological malignancies, including leukemia and lymphoma subtypes listed in the document.
Anti-leukemia activity via combination regimens including Compound 1 with azacitidine and venetoclax in FLT3-WT AML cell lines, including reported synergistic activity [procedural detail omitted for safety].
Interested in licensing this patent?